Image

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

Recruiting
18 - 75 years of age
Both
Phase 1

Powered by AI

Overview

This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

Description

Background

  • B7-H3 is expressed in 70% of patients with glioblastoma
  • B7-H3 is not expressed in normal tissues especially not in central nervous system. Therefore, it is an attractive GBM target for CAR-T therapy
  • The investigators constructed a retroviral vector encoding a chimeric antigen receptor (CAR) targeting B7-H3, which can mediate CAR transfer into patient T cells with high efficiency.

Objectives

  • To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles
  • To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data
  • To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles

Design

Patients autologous T cells are activated and transduced with retrovirus containing B7-H3 CAR. CAR-T cells are expanded ex vivo and infused back to patients via intratumoral or intracerebroventricular injection through an Ommaya catheter. 3 injections of CAR-T are planned at two different doses with 1-2 weeks intervals. The CAR-T injections occur in between Temozolomide (TMZ) cycles. Temozolomide treatment in the cycle of CAR-T injections will be stopped and resumed next cycle. Patients may receive additional CAR-T cycles at the discretion of the principal investigator and oncologist.

Eligibility

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative.
  • Histologically confirmed diagnosis of World Health Organization (WHO) classification grade IV glioblastoma (GBM).
  • Clinical Pathology confirms B7-H3 positive tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50).
  • Relapsed/refractory disease confirmed by radiographic evidence after standard therapy.
  • Suitable for the surgery of the placement of the Ommaya catheter.
  • Eastern Cooperative Oncology Group (ECOG) =0 or 1 (need to be confirmed before intratumoral or intracerebroventricular injection)
  • >= 8 weeks after completion of front-line radiation therapy
  • >= 6 weeks after completion of nitrourea chemotherapy
  • >= 14 days after completion of Temozolomide or other chemotherapy
  • 2 weeks of wash-out time after completion of targeted therapy with related adverse events (AE) on baseline (4 weeks for Bevacizumab).
  • Patients with other chronic AEs are in the investigator's judgement
  • Blood cell count: White blood count (WBC) >= 2000/μL;Neutrophil count >= 1500/μL;Platelets >= 100 x 103/μL;Hemoglobin >= 9.0 g/dL
  • Serum Creatinine <= 1.5×ULN or Creatinine Clearance Rate (Cockcroft and Gault) > 30 mL/min/1.73 m2
  • Alanine Transaminase (ALT) <= 5×ULN and total bilirubin < 2.0mg/dL
  • Lung function: Oxygen (O2) saturation >= 92% on room air and < CTCAE grade 1 dyspnea
  • Heart function: Left ventricular ejection fraction (LVEF) >= 40% by multigated acquisition (MUGA) scan or echocardiogram
  • Normal coagulation function: prothrombin time (PT),activated partial thromboplastin time (APTT) and international normalized ratio (INR)
  • Good blood vessel condition for leukapheresis
  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test
  • Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity within one year after B7-H3 CAR-T infusion

Exclusion Criteria:

  • Other active malignancy in the past 2 years except non-melanoma skin cancer, completely surgical removed low grade tumor, posttherapeutic limited-stage prostate cancer, biopsy confirmed in situ cervical carcinoma, PAP test confirmed squamous intraepithelial lesions
  • Participant is undergoing or planning to take other anti-tumor therapies
  • Participant is systematic steroid-dependent, or is expecting to be treated with systematic steroid
  • Active immunodeficiency virus (HIV) or hepatitis B or hepatitis C virus infection
  • Active infection from fungi, bacteria and/or viruses
  • Known history of the following cardiac diseases in the past 6 months:
  • New York Heart Association (NYHA) defined grade III or IV heart failure, cardiac angioplasty, myocardial infarction, unstable angina and other clinically significant heart diseases
  • Known history and/or clinically evident central nerve system diseases: seizure, epileptic seizure, aphasia, paralysis, stroke, severe brain damage, dementia, Parkinson's Disease, cerebellar diseases, organic brain syndrome and psychiatric disorders
  • Autoimmune diseases
  • Pregnant or breastfeeding females
  • Therapeutic doses of corticosteroid within 7 days before leukapheresis or 72 hours before B7-H3 CAR-T infusion
  • Cytotoxic chemotherapy without lymphocytotoxicity within 1 week before leukapheresis except that the treatment has been stopped for more than 3 half-lives of the drug
  • Lymphocytotoxic chemotherapy (cyclophosphamide, Ifosfamide and bendamustine) within 2 weeks before leukapheresis
  • Other clinical trials drugs within 4 weeks before leukapheresis except that the drug has no effect or the disease has progressed, and the treatment has been stopped for more than 3 half-lives of the drug
  • Radiotherapy within 6 weeks before leukapheresis
  • Prior trials of CAR-T or other cell therapy
  • Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Study details

Recurrent Glioblastoma, Refractory Glioblastoma

NCT04385173

Second Affiliated Hospital, School of Medicine, Zhejiang University

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.